Acromegaly is treated primarily with surgery to remove the pituitary tumor causing excess growth hormone, followed by medications or radiation when surgery alone doesn’t achieve full control. Most people with acromegaly need a combination of approaches, and the specific plan depends on the size and location of the tumor, how elevated hormone levels are, and how the body responds to each step of treatment.
Surgery Is the First-Line Treatment
The standard operation for acromegaly is transsphenoidal surgery, where a surgeon reaches the pituitary tumor through the nose and sinuses rather than opening the skull. This approach avoids visible scarring and typically means a shorter recovery. The goal is to remove enough of the tumor to bring growth hormone and IGF-1 (a related hormone produced by the liver) back to normal levels.
How well surgery works depends heavily on tumor size. Small tumors (microadenomas, under 10 mm) have remission rates of 56% to 100%. Larger tumors (macroadenomas) are harder to fully remove, with remission rates ranging from roughly 28% to 61%. Two factors strongly predict whether surgery will succeed: how high IGF-1 levels are before the operation, and whether the tumor has grown into the cavernous sinus, a bony space on either side of the pituitary that makes complete removal difficult.
Even when surgery doesn’t cure acromegaly outright, removing most of the tumor can lower hormone levels enough to make medications work better afterward. Your first follow-up MRI is typically scheduled no sooner than three months after surgery, giving the surgical site time to heal before doctors assess what’s left.
Medications That Lower Growth Hormone
When surgery doesn’t fully normalize hormone levels, or when a tumor can’t be safely removed, medications become the main treatment. There are three classes of drugs used, each working through a different mechanism.
Somatostatin Receptor Ligands
These are the most commonly prescribed medications for acromegaly. They mimic a natural brain chemical called somatostatin, which tells the pituitary gland to stop releasing growth hormone. They also reduce IGF-1 production in the liver and can shrink the tumor itself over time.
The two first-generation options are given as injections every four weeks. One is a long-acting injection into the muscle, typically starting at 20 mg per month and adjusted up to 30 or even 60 mg based on how well hormone levels respond. The other is a deep injection under the skin, usually starting at 90 mg monthly. These medications achieve full biochemical control in roughly 33% to 85% of patients, depending on the study and the dose used. The wide range reflects differences in tumor biology: some tumors are simply more responsive than others.
For people who respond well to these injections but want to avoid monthly shots, an oral capsule form is now available. Approved by the FDA, it’s specifically for patients who have already shown they respond to and tolerate injection-based treatment. It’s taken as a daily pill rather than a monthly injection.
Growth Hormone Receptor Blockers
This type of medication works differently. Instead of reducing how much growth hormone the tumor makes, it blocks growth hormone from attaching to receptors throughout the body. This effectively prevents the hormone from triggering IGF-1 production and causing the symptoms of acromegaly.
This approach is particularly effective for people whose disease hasn’t responded to somatostatin-based drugs. In clinical trials, IGF-1 levels normalized in up to 95% of patients who were resistant to other medications. Real-world results are somewhat lower, around 65% to 70%, largely because doses aren’t always increased enough. When the dose is properly adjusted upward, normalization rates climb back toward 90%. The medication is given as a daily injection under the skin.
Dopamine Agonists
Dopamine agonists are oral pills originally developed for a different type of pituitary tumor. They play a supporting role in acromegaly, most often added on top of somatostatin-based drugs when those alone aren’t quite enough. They work best in people whose hormone levels are only mildly to moderately elevated. In one study, adding a dopamine agonist reduced IGF-1 levels by about 32% and growth hormone levels by about 34% on average.
The best candidates are patients whose IGF-1 is less than about 2.2 times the upper limit of normal. In that group, remission rates reached 82%. For patients with higher levels, the response dropped to around 31%. This makes dopamine agonists a useful tool for fine-tuning control rather than tackling severely elevated hormones.
Radiation for Persistent Disease
Radiation therapy is generally reserved for tumors that persist or regrow after surgery and don’t respond adequately to medications. The most common modern approach is stereotactic radiosurgery, which delivers a focused beam of radiation to the tumor in a single session, minimizing exposure to surrounding brain tissue.
The main drawback of radiation is patience. The average time to durable remission after stereotactic radiosurgery is about 38 months, meaning most people continue taking medications for three or more years while waiting for the radiation’s full effect. The range is enormous: some patients respond within months, while others take over a decade.
Radiation also carries a significant risk of damaging the normal pituitary gland. About 26% of patients develop at least one new hormone deficiency afterward, with 11% losing function in multiple hormone systems. This means lifelong hormone replacement therapy for conditions like low thyroid, low cortisol, or low sex hormones. Nerve damage affecting vision or eye movement occurs in about 4% of cases.
Managing Related Health Problems
Acromegaly doesn’t just affect growth hormone. Years of excess hormone exposure can cause high blood pressure (affecting roughly a third of patients), heart valve problems, heart rhythm abnormalities, diabetes, and sleep apnea. Treating the underlying tumor helps, but these complications often need their own management.
Blood sugar control deserves special attention because some acromegaly medications can worsen it. Certain newer somatostatin-based drugs are particularly prone to raising blood sugar. Current expert recommendations suggest treating this type of medication-induced high blood sugar with specific diabetes drugs that work on the gut hormone system, rather than defaulting to insulin. For patients with existing heart or kidney disease, a different class of diabetes medication may be preferred. Your endocrinologist will typically coordinate this alongside your acromegaly treatment.
What Treatment Success Looks Like
The target of treatment is an IGF-1 level within the normal range for your age. This is the single most important number for tracking whether acromegaly is controlled. When IGF-1 normalizes, the progression of symptoms slows or stops, soft tissue swelling decreases, joint pain often improves, and the excess health risks from the disease begin to drop.
Monitoring continues for years. Current consensus guidelines recommend biochemical follow-up for at least five years, with the schedule tailored to your specific situation. If you’re on medication-based treatment, an MRI is typically done six months after starting or switching drugs. After that, routine MRI scans aren’t always necessary. Instead, imaging is guided by blood test results and symptoms, particularly any new visual changes. This individualized approach avoids unnecessary scans while catching problems that matter.
Most people with acromegaly end up on some form of long-term treatment, whether it’s medication, hormone replacement after radiation, or ongoing monitoring after a successful surgery. The condition is manageable, and the combination of surgical, medical, and radiation options means there’s almost always a path to getting hormone levels under control.